Spero Therapeutics closed at $1.07 on Nov 4, up 2.88%, within 2.9% of its 52-week closing low. Volume of 210.3K shares was 0.56× its 20-day average (below normal).
Split-adjusted performance: -10.1% over one month, -57.7% over six months, -55.0% over one year.
Short interest was 840.5K shares at the Oct 15 settlement, up 5.8% from the prior report (2.0% of float, 1.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SPROSpero Therapeutics | $1.07 | +2.88% | −57.7% | −100.0% | — | 8.4 | $62.3M | |
| QUCYQuantum Cyber N.V | $0.7430 | +2.65% | — | — | — | — | $62.5M | Compare |
| GOSSGossamer Bio | $9.95 | +7.22% | −64.5% | −19.6% | 182.9% | — | $60.9M | Compare |
| TELOTelomir Pharmaceuticals | $0.8750 | −3.85% | −34.7% | — | — | — | $64.5M | Compare |
| XBITXBiotech | $1.95 | −2.01% | −23.5% | — | — | — | $59.5M | Compare |
| VRCAVerrica Pharmaceuticals | $3.46 | +5.02% | −59.0% | −53.8% | −224.4% | — | $59.4M | Compare |
| RNXTRenovoRx | $1.31 | +1.55% | +47.2% | +115.4% | −320.2% | — | $59.1M | Compare |
| FBIOFortress Biotech | $1.97 | +1.55% | −22.7% | +14.0% | −13.2% | 0.6 | $65.7M | Compare |
| RANIRani Therapeutics Holdings | $0.5728 | +3.06% | −40.3% | — | −432.7% | — | $66.1M | Compare |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
